アジア太平洋地域の難治性てんかん治療市場：分析・予測 (2025-2035年)

アジア太平洋地域の難治性てんかん治療の市場規模は、2024年の10億4,470万米ドルから、予測期間中はCAGR 8.18%で推移し、2035年には24億8,180万米ドルに成長すると予測されています。

同地域では、難治性てんかんの治療において、患者のライフスタイル、遺伝的要因、臨床歴などを考慮した、より個別化された治療モデルが採用されています。同地域の医療従事者たちは、遺伝学、分子診断、データ駆動型ツールの進展を活用し、従来の一律対応から脱却し、個々の患者に最適化された治療計画を策定しています。このようなカスタマイズされたアプローチにより、試行錯誤による薬剤調整の必要性が減り、発作のコントロールが改善されると同時に、副作用の軽減にもつながっています。

地域ごとのイニシアティブにより、リアルワールドデータや臨床レジストリの活用が促進されており、アジア太平洋地域全体で規制の枠組みも、革新的な抗てんかん治療の承認・検証を支援する方向に変化しています。予測分析を用いた薬剤耐性患者の早期発見により、神経調節療法や精密標的薬への迅速なアクセスが可能となっています。研究機関、てんかん専門センター、医療技術開発企業の連携によって、早期診断と治療最適化の進展が加速しています。中国、インド、韓国、日本などで精密神経医療ネットワークが拡大する中、患者治療はより効果的かつ成果重視のものとなっており、これがQOLの向上と、より経済的な医療提供の両立を支えています。

同地域の難治性てんかん治療市場は、先進国と新興国の両方で薬剤耐性てんかんの有病率が上昇していることを背景に、急速な成長を遂げています。2種類以上の抗てんかん薬（AED）に反応しない発作は難治性てんかんと呼ばれ、深刻な健康・経済的負担をもたらします。そのため、地域の医療システムは、精密医療、神経調節療法（脳深部刺激や迷走神経刺激など）、低侵襲手術といった先進的治療法を徐々に導入しています。

遺伝子解析、神経画像診断、脳波（EEG）モニタリングなどの技術進歩により、薬剤耐性患者のより早期かつ正確な診断が可能となり、個別化された集中的な治療計画の策定が進んでいます。AIを活用した診断、先進的なAED製剤、革新的な外科手術技術の臨床導入を主導しているのは、中国、インド、韓国、日本などの国々です。

ただし、治療費の高騰、専門的医療へのアクセス格差、一般市民の認知度の低さといった課題は依然として存在し、一部地域では最適な治療成果の実現を妨げています。これらの格差は、医療インフラへの投資拡大、保険制度の整備、規制環境の改善によって徐々に埋められつつあります。このような背景から、アジア太平洋地域は難治性てんかん治療分野における成長と革新の重要市場として注目されています。

市場の分類：

セグメンテーション1：地域別

• アジア太平洋
  • 日本
  • インド
  • 中国
  • オーストラリア
  • 韓国
  • その他

当レポートでは、アジア太平洋地域の難治性てんかん治療の市場を調査し、主要動向、市場影響因子の分析、法規制環境、技術・特許の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

範囲と定義

第1章 市場：業界展望

• 主要動向
• 難治性てんかん治療市場の動向
  • 難治性てんかん治療のための新たな標的療法
  • 事業戦略
  • 企業戦略
  • 市場機会
• パイプライン薬：難治性てんかん治療
• 動向
  • 難治性てんかん治療のための新たな標的療法
• 市場力学
  • 動向、促進要因、課題、機会：現在および将来の影響評価
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の課題

第2章 地域

• 地域サマリー
• アジア太平洋
  • 地域概要
  • 市場成長の原動力
  • 市場課題
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • その他

第3章 市場：競合ベンチマーキングと企業プロファイル

• Eisai, Inc.
• SK Biopharmaceuticals
  • 概要
  • 主要製品/製品ポートフォリオ
  • 主要競合
  • ターゲット顧客
  • 戦略的ポジショニングと市場への影響
  • アナリストの見解
  • 研究イニシアチブ

第4章 調査手法

List of Figures

• Figure 1: Asia-Pacific Refractory Epilepsy Treatment Market (by Scenario), $Million, 2024, 2028, and 2035
• Figure 2: Asia-Pacific Refractory Epilepsy Treatment Market, 2024-2035
• Figure 3: Timeline of Drugs Launched for Refractory Epilepsy Treatment
• Figure 4: Asia-Pacific Refractory Epilepsy Treatment Market Snapshot
• Figure 5: Refractory Epilepsy Treatment Market, $Million, 2024 and 2035
• Figure 6: Surgical Procedures Performed on Patients with Medication-Resistant Epilepsy Treatment in Africa
• Figure 7: Asia-Pacific Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 8: China Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 9: Japan Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 10: India Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 11: South Korea Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 12: Australia Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 13: Rest-of-Asia-Pacific Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 14: Inclusion and Exclusion
• Figure 15: Data Triangulation
• Figure 16: Top-Down and Bottom-Up Approach
• Figure 17: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Recent Investments in Refractory Epilepsy Treatment
• Table 3: Key Development in Seizure Management by Key Companies
• Table 4: Pipeline Drugs and its Clinical Trial Phase
• Table 5: Recent Investments in Refractory Epilepsy Treatment
• Table 6: Major Development in the Refractory Epilepsy Treatment Market
• Table 7: Major Development in Refractory Epilepsy Treatment Market
• Table 8: Major Drugs and Their Indication
• Table 9: Major Devices Used in the Refractory Epilepsy Treatment Market
• Table 10: Refractory Epilepsy Treatment Market (by Regio), $Million, 2023-2035
• Table 11: Asia-Pacific Refractory Epilepsy Treatment Market (By Country), $Million, 2023-2035

This report can be delivered in 2 working days.

Introduction to Asia-Pacific Refractory Epilepsy Treatment Market

The Asia-Pacific refractory epilepsy treatment market is projected to reach $2,481.8 million by 2035 from $1,044.7 million in 2024, growing at a CAGR of 8.18% during the forecast period 2025-2035. Refractory epilepsy is being treated in the APAC region using a more individualized paradigm that takes into account the lifestyle, genetics, and clinical history of each patient. Healthcare professionals around APAC are utilizing developments in genetics, molecular diagnostics, and data-driven tools to create personalized treatment plans, going beyond the conventional """"one-size-fits-all"""" approach. This customized strategy decreases the need for trial-and-error medication adjustments while simultaneously improving seizure control and lowering adverse effects.

While regional initiatives are encouraging the use of real-world data and clinical registries, regulatory frameworks throughout APAC are changing to assist the approval and validation of novel anti-seizure treatments. Timely access to neuromodulation therapies and precision-targeted medications is made possible by the early detection of drug-resistant patients using predictive analytics. Advances in early diagnosis and treatment optimization are being fueled by collaboration between research institutions, specialized epilepsy centers, and medtech developers. Patient treatment is becoming more effective and outcome-driven as precision neurology networks grow in nations like China, India, South Korea, and Japan. This supports both better quality of life and more economical healthcare delivery.

Market Introduction

The APAC refractory epilepsy treatment market is experiencing rapid growth, driven by a rising prevalence of drug-resistant epilepsy across both developed and emerging nations in the area. Seizures that are not responding to two or more anti-epileptic medications (AEDs) are known as refractory epilepsy, and they present serious health and financial difficulties. As a result, healthcare systems around Asia-Pacific are progressively implementing cutting-edge therapeutic approaches like precision medicine, neuromodulation (such as deep brain stimulation and vagus nerve stimulation), and minimally invasive surgery.

Technological developments in genetic analysis, neuroimaging, and EEG monitoring are making it possible to diagnose drug-resistant patients earlier and with more accuracy, allowing for more individualized and focused treatment plans. Leading nations in incorporating AI-driven diagnostics, cutting-edge AED formulations, and creative surgical techniques into routine care routes include China, India, South Korea, and Japan.

Even with significant advancements, issues including exorbitant treatment expenses, unequal access to specialized care, and low public awareness still prevent some areas of the region from seeing the best possible treatment results. These disparities are being filled, meanwhile, by rising investments in healthcare infrastructure, increased insurance coverage, and encouraging regulatory frameworks. Because of this, the APAC area is becoming a vital market for advancement and expansion in the treatment of refractory epilepsy.

Market Segmentation

Segmentation 1: By Region

• Asia-Pacific
  • Japan
  • India
  • China
  • Australia
  • South Korea
  • Rest-of-Asia-Pacific

APAC Refractory Epilepsy Treatment Market Trends, Drivers and Challenges

Trends

• Anti-epileptic drugs (AEDs) continue to dominate the market, though neuromodulation and surgical interventions are gaining traction.
• APAC is experiencing steady market growth, in line with global trends.
• Pediatric cases and focal epilepsy remain the most commonly treated segments in refractory epilepsy care.
• Integration of precision medicine and advanced diagnostics is shaping more personalized treatment approaches.
• Minimally invasive techniques such as laser ablation and neurostimulation are becoming more widely adopted.

Drivers

• High prevalence of drug-resistant epilepsy, especially in densely populated countries.
• Introduction of newer-generation medications offering better seizure control and fewer side effects.
• Increasing adoption of neuromodulation therapies like vagus nerve stimulation (VNS), deep brain stimulation (DBS), and responsive neurostimulation (RNS).
• Advancements in imaging, EEG analytics, and genomics supporting individualized treatment strategies.
• Rising healthcare investments and improved access to specialty care in urban centers.

Challenges

• High costs of newer drugs and neuromodulation devices limit access in low- and middle-income areas.
• Many drug-resistant cases go undiagnosed due to lack of awareness or limited diagnostic capacity.
• Shortage of specialized epilepsy care centers and trained neurosurgeons in rural regions.
• Social stigma and misinformation often delay treatment or lead to underreporting of symptoms.
• Limited insurance coverage for advanced therapies in several APAC countries.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in refractory epilepsy treatment, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new Refractory Epilepsy Treatment solutions.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• SK Biopharmaceuticals
• Eisai, Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Major Trend
• 1.2 Trend in Refractory Epilepsy Treatment Market
  • 1.2.1 Emerging Targeted Therapy for Refractory Epilepsy Treatment
  • 1.2.2 Business Strategies
    • 1.2.2.1 Product Developments
    • 1.2.2.2 Market Developments
  • 1.2.3 Corporate Strategies
    • 1.2.3.1 Partnerships and Joint Ventures
  • 1.2.4 Market Opportunities
    • 1.2.4.1 Advances in Neuromodulation Devices in the Refractory Epilepsy Treatment Market
    • 1.2.4.2 Shift from Neo-Adjuvant Approaches Driven by Diagnostic Advancements
• 1.3 Pipeline Drugs, Refractory Epilepsy Treatment
• 1.4 Trends
  • 1.4.1 Emerging Targeted Therapy for Refractory Epilepsy Treatment
• 1.5 Market Dynamics
  • 1.5.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • 1.5.2 Market Drivers
    • 1.5.2.1 Increasing Prevalence of Drug-resistant Epilepsy and Ever-expanding Pipeline of Novel Therapeutics
    • 1.5.2.2 Growing Impact of Orphan Drug Development and Role of Advocacy Groups and Awareness Programs
    • 1.5.2.3 Emerging Treatment Modalities in Refractory Epilepsy
  • 1.5.3 Market Restraints
    • 1.5.3.1 Off-Label Medication Practices Hindering the Refractory Epilepsy Treatment Market
    • 1.5.3.2 High R&D Cost as a Barrier to New Entry for New and Small-Scale Companies
  • 1.5.4 Market Opportunities
    • 1.5.4.1 Advances in Neuromodulation Devices in the Refractory Epilepsy Treatment Market
    • 1.5.4.2 Shift from Neo-Adjuvant Approaches Driven by Diagnostic Advancements
  • 1.5.5 Market Challenges
    • 1.5.5.1 Financial Constraints on Patient Access
    • 1.5.5.2 Underdiagnosis of Patients who Meet the Criteria for Drug-Resistant Epilepsy (DRE)

2 Region

• 2.1 Regional Summary
• 2.2 Asia-Pacific
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 China
  • 2.2.5 Japan
  • 2.2.6 India
  • 2.2.7 South Korea
  • 2.2.8 Australia
  • 2.2.9 Rest-of-Asia-Pacific

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Eisai, Inc.
  • 3.1.1 Overview
  • 3.1.2 Top Products/Product Portfolio
  • 3.1.3 Top Competitors
  • 3.1.4 Strategic Positioning and Market Impact
  • 3.1.5 Key Personal
  • 3.1.6 Analyst View
  • 3.1.7 Research Initiatives
• 3.2 SK Biopharmaceuticals
  • 3.2.1 Overview
  • 3.2.2 Top Products/Product Portfolio
  • 3.2.3 Top Competitors
  • 3.2.4 Target Customers
  • 3.2.5 Strategic Positioning and Market Impact
  • 3.2.6 Analyst View
  • 3.2.7 Research Initiatives

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Inclusion and Exclusion
  • 4.1.4 Data Triangulation
• 4.2 Market Estimation and Forecast